IL-2
Information
- Drug Name
- IL-2
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| NK cells require DNAM-1 for natural or cytokine (I... | CD226 | CD226 UNDEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| In this phase I-II trial, there is no evidence to ... | CTLA4 | CTLA4 UNDEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| High-dose IL-2. Vascular endothelial growth factor... | VEGFA | VEGFA EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04155710 | Active, not recruiting | Phase 1/Phase 2 | Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL | February 19, 2020 | September 2025 |
| NCT00001564 | Completed | Phase 2 | A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas | December 23, 1996 | October 25, 2007 |
| NCT00001705 | Completed | Phase 2 | Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence | July 1998 | June 2001 |
| NCT00001832 | Completed | Phase 2 | Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma | August 1999 | May 2010 |
| NCT00080353 | Completed | Phase 2 | Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma | March 2004 | December 2008 |
| NCT00100906 | Completed | Phase 2 | Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer | August 2004 | July 2013 |
| NCT00101101 | Completed | Phase 2 | Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma | July 2004 | June 14, 2021 |
| NCT00110812 | Completed | Phase 2 | Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People | September 2005 | February 2011 |
| NCT00001430 | Completed | Phase 2 | A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas | February 1995 | January 2002 |
| NCT00314106 | Completed | Phase 2 | Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | April 2006 | March 2009 |
| NCT00325507 | Completed | Phase 2 | Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma | November 2005 | July 2008 |
| NCT00328861 | Completed | Phase 2 | Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer | May 2006 | April 2009 |
| NCT00352885 | Completed | Phase 4 | Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment | October 6, 2006 | May 17, 2010 |
| NCT00470015 | Completed | Phase 1 | Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma | March 2007 | January 2, 2013 |
| NCT00525889 | Completed | Phase 1 | Proleukin and Rapamune in Type 1 Diabetes | August 2007 | September 2013 |
| NCT00539695 | Completed | Phase 2 | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD | June 2007 | March 2014 |
| NCT00609401 | Completed | Phase 2 | Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) | November 2006 | May 2008 |
| NCT00952237 | Completed | Phase 1 | Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF | January 2003 | April 2011 |
| NCT00968760 | Completed | Phase 1 | CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | June 20, 2011 | April 23, 2020 |
| NCT01105650 | Completed | Phase 2 | Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | July 2010 | April 2014 |
| NCT01278940 | Completed | Phase 1/Phase 2 | Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma | March 2002 | December 2015 |
| NCT01288963 | Completed | IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma | February 2010 | December 2020 | |
| NCT01550367 | Completed | Phase 1/Phase 2 | Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) | March 2012 | February 2019 |
| NCT01603212 | Completed | Phase 1 | Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor | July 18, 2013 | July 5, 2017 |
| NCT01896271 | Completed | Phase 2 | High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer | October 2, 2013 | April 20, 2021 |
| NCT01927120 | Completed | Phase 2 | In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis | March 25, 2014 | March 9, 2017 |
| NCT02118285 | Completed | Phase 1 | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | July 28, 2014 | November 12, 2015 |
| NCT02130869 | Completed | Phase 1 | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | October 10, 2014 | December 20, 2017 |
| NCT02763475 | Completed | Phase 2 | NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents | May 2016 | August 2020 |
| NCT03039673 | Completed | Phase 2 | MIROCALS: Modifying Immune Response and OutComes in ALS | June 19, 2017 | July 22, 2021 |
| NCT03841110 | Completed | Phase 1 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | February 15, 2019 | November 15, 2022 |
| NCT04327037 | Completed | Phase 1 | Safety of Expanded Haploidentical Natural Killer Cells for Leukemia | January 2, 2019 | June 30, 2021 |
| NCT04387942 | Completed | N/A | The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura | June 14, 2020 | June 30, 2022 |
| NCT04397107 | Completed | N/A | The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases | August 15, 2020 | June 30, 2022 |
| NCT04630769 | Completed | Phase 1 | FT516 and IL2 With Enoblituzumab for Ovarian Cancer | April 2, 2021 | January 1, 2022 |
| NCT05648994 | Not yet recruiting | Early Phase 1 | TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors | December 2022 | March 2026 |
| NCT06107894 | Not yet recruiting | Phase 1 | TIL Therapy for Patients With Advanced Solid Tumors | January 2024 | May 2026 |
| NCT06255028 | Not yet recruiting | Phase 1 | A Study of CNTY-101 in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) | August 2024 | August 2028 |
| NCT05649618 | Not yet recruiting | Early Phase 1 | TIL Cells for the Treatment of the Advanced Solid Tumors Patients | December 5, 2022 | March 2026 |
| NCT05530200 | Not yet recruiting | Phase 2 | PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors. | September 2022 | June 2025 |
| NCT05603013 | Not yet recruiting | Phase 2 | Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0) | October 30, 2022 | October 17, 2024 |
| NCT04625205 | Recruiting | Phase 1 | NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma | December 1, 2020 | October 31, 2025 |
| NCT03474497 | Recruiting | Phase 1/Phase 2 | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | May 20, 2019 | December 2023 |
| NCT05881525 | Recruiting | Phase 1 | NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors | June 1, 2023 | March 2025 |
| NCT05400122 | Recruiting | Phase 1 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | September 9, 2022 | June 1, 2026 |
| NCT04629729 | Recruiting | Phase 1 | FT819 in Subjects With B-cell Malignancies | July 26, 2021 | September 30, 2039 |
| NCT04347616 | Recruiting | Phase 1/Phase 2 | Natural Killer-cell Therapy for Acute Myeloid Leukemia | December 3, 2020 | September 1, 2025 |
| NCT06158828 | Recruiting | Phase 1/Phase 2 | Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML | May 15, 2024 | May 31, 2030 |
| NCT05357027 | Recruiting | Phase 1/Phase 2 | HPV16 E6 TCR T Cells for Cervical Carcinoma | August 10, 2022 | August 31, 2025 |
| NCT05336409 | Recruiting | Phase 1 | A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies | January 24, 2023 | August 2027 |
| NCT04892498 | Recruiting | Phase 2 | Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0) | May 30, 2021 | August 2024 |
| NCT03166397 | Recruiting | Phase 2 | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | June 5, 2017 | June 1, 2026 |
| NCT06302062 | Recruiting | Phase 1 | Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors | June 6, 2023 | June 30, 2026 |
| NCT03970382 | Suspended | Phase 1 | A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | July 3, 2019 | August 12, 2022 |
| NCT01106950 | Terminated | Phase 2 | Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML) | July 2010 | December 2012 |
| NCT03241719 | Terminated | Early Phase 1 | Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA | October 17, 2017 | July 21, 2021 |
| NCT04023071 | Terminated | Phase 1 | FT516 in Subjects With Advanced Hematologic Malignancies | October 4, 2019 | October 23, 2023 |
| NCT00196651 | Terminated | Phase 2 | HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection | August 2000 | February 2004 |
| NCT00203866 | Terminated | Phase 2 | Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma | October 2003 | March 2007 |
| NCT00089778 | Terminated | Phase 2 | Vaccine Treatment of Kidney Cancer | September 10, 2004 | August 5, 2008 |
| NCT04551885 | Terminated | Phase 1 | FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | September 7, 2020 | August 11, 2023 |
| NCT04596033 | Terminated | Phase 1 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | November 11, 2020 | June 27, 2022 |
| NCT00913913 | Terminated | Phase 2 | Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients | February 2009 | January 2013 |
| NCT05395052 | Terminated | Phase 1 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | May 31, 2022 | August 11, 2023 |
| NCT01898793 | Terminated | Phase 1/Phase 2 | Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | August 11, 2014 | April 4, 2022 |
| NCT02173093 | Unknown status | Phase 1/Phase 2 | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | November 2014 | December 2019 |
| NCT03175705 | Unknown status | Phase 1 | Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC | May 1, 2017 | March 30, 2019 |
| NCT03175679 | Unknown status | Phase 1 | Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC | May 1, 2017 | March 30, 2019 |
| NCT04136106 | Unknown status | The Incidence of Infection in Treatment of Low-dose IL-2 of SLE Patients | July 1, 2019 | December 30, 2021 | |
| NCT03412526 | Unknown status | Phase 2 | Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian | January 21, 2018 | February 1, 2022 |
| NCT04952155 | Unknown status | Phase 2 | Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome | January 1, 2020 | December 31, 2022 |
| NCT00224354 | Withdrawn | Phase 1 | Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells | September 2005 | December 2009 |
| NCT03222089 | Withdrawn | Phase 2 | Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC | July 20, 2017 | July 20, 2020 |
| NCT02863913 | Withdrawn | Phase 1 | PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer | September 2016 | September 2019 |
| NCT02867345 | Withdrawn | PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer | November 2016 | December 2020 | |
| NCT02867332 | Withdrawn | Phase 1 | PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma. | November 2016 | November 2020 |